Modern multimodality therapy for pediatric nonorbital parameningeal sarcomas.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 20175111.
- Also identified by DOI 10.1002/hed.21353.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nonorbital parameningeal sarcomas are rare, aggressive tumors that arise predominantly in the pediatric population. The purpose of this study was to review their management and to clarify the role of surgery in their treatment. Treatment, prognostic factors, and outcomes for patients over a 10-year period were reviewed. In all, 34 patients were identified. The most common tumor site was the maxillary sinus, and 73% were rhabdomyosarcoma. Six patients (18%) presented with positive nodal metastases and 3 patients (10%) presented with distant metastases. Overall, 18 patients were treated surgically. Locoregional recurrence rate was 43%; no patients developed distant recurrence. Five-year overall survival was 66.8%, disease-specific survival was 68.1%, and disease-free survival was 31.9%. Pediatric nonorbital parameningeal sarcomas require aggressive multimodality treatment. Although chemotherapy and radiation constitute the treatment of choice in most cases, surgery may have a role as salvage therapy and in cases that fail to respond to chemoradiation.
Medical subject headings
- Nasopharyngeal Neoplasms
- Nose Neoplasms
- Sarcoma